May 25, he is long on HIMX at 6,7 ,then downhill to 5, now 7. Success!!! Wow.
June 4, Long on CLSN. Stock was this day on local maximum 1,9 , record volume, „good“ entry point. Now 1,3.
June 5, he is short MCP near 6. In two weeks MCP fall to 5 so maybe he´s cover. But I doubt. His article is very negative, he predict down to pennies. MCP closed at 7 yesterday.
Jun 13. Stock2pro declared he may initiate a long position in SWY over the next 72 hours. Maybe he becomes shy after losses. SWY was on „good“ entry point to buy (again), stock was on nice top near 25 with huge volume. Maybe he delay 72 hours, then he buy at 24. Now 26. Great job. Goldmans will hire him one day.
And now SNTA. By his opinion, Kovner and his people are fraudsters. They buy at 3,8, then say we have breast cancer and sell all. Stock2pro have no evidence for this. Man, change your medical or don´t mix that pills.
Stock2pro also think, Enchant phase 2 will fail. No information why. Core feeling probably.
This is really funny. But maybe he is smarter and buy/short before his Seeking Alpha stories. This is man to follow.
This Stock2pro is an absolute joke. As far as Enchant-1, I guess he never heard of two stage phase I/II trial where a specified number of tumor responses are needed for a trial to move into the second stage. I guess he doesn't understand that when said trial meets, or in SNTA's case, exceeded the threshold for moving to stage II, it is a material event so must be reported to shareholders. Even more laughable is that ENCHANT-2 hasn't even been designed yet, so how in the world can you say it will fail. It will almost certainly be a combination study rather than Ganetespib as a single agent as it was for the early data released so far in Enchant-1. Hell, even Encant-1 as a combination component with Ganetespib + Paclitaxel, although data form that trial arm hasn't been generated yet.